YS Biopharma granted new patent covering PIKA YS-HBV-002

YS Biopharma announced that the United States Patent and Trademark Office has issued it a patent covering the company’s PIKA YS-HBV-002, an immunotherapeutic vaccine designed to treat patients suffering from chronic hepatitis B virus infection. YS Biopharma expects to submit an Investigational New Drug application and commence the clinical development of PIKA YS-HBV-002 as a novel immunotherapy for the treatment of chronic HBV infection in 2024.